EUVIMEDEUVIMED entdecken
Crossref

Oxaliplatin lipidated prodrug synergistically enhances the anti-colorectal cancer effect of IL12 mRNA

Hui Liu, Yating Du, Desheng Zhan, Wenjun Yu, Yan Li, Aiping Wang, Jianpeng Yin, Haiqiang Cao, Yuanlei Fu iD

Drug Delivery and Translational Research · 2024

DOI: 10.1007/s13346-024-01540-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Delivery and Translational Research, 2024. Verfasst von Hui Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs, Universities of Shandong, Key Laboratory of M…. Hauptthemen laut MEDLINE: Oxaliplatin, Prodrugs, Colorectal Neoplasms, Interleukin-12. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Department of Science and Technology of Shandong Province, Yantai Science and Technology Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) is the fourth most common cancer in the world, with the second highest incidence rate after lung cancer. Oxaliplatin (OXA) is a broad-spectrum anti-tumor agent with significant therapeutic efficacy in colorectal cancer, and as a divalent platinum analog, it is not selective in its distribution in the body and has systemic toxicity with continued use. Interleukin-12 (IL12) is an immunostimulatory cytokine with cytokine monotherapy that has made advances in the fight against cancer, limiting the clinical use of cytokines due to severe toxicity. Here, we introduced a long alkyl chain and N-methyl-2,2-diaminodiethylamine to the ligand of OXA to obtain OXA-LIP, which effectively reduces its toxicity and improves the uptake of the drug by tumor cells. We successfully constructed IL12 mRNA and used LNPs to deliver IL12 mRNA, and in vivo pharmacodynamic studies demonstrated that OXA-LIP combined with IL12 mRNA had better tumor inhibition and higher biosafety. In addition, it was investigated by pharmacokinetic experiments that the OXA-LIP drug could accumulate in nude mice at the tumor site, which prolonged the half-life and enhanced the anti-tumor efficiency of OXA. It is hoped that these results will provide an important reference for the subsequent research and development of OXA-LIP with IL12 mRNA, as well as provide new therapeutic approaches for the treatment of colon cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OxaliplatinProdrugsColorectal NeoplasmsInterleukin-12Antineoplastic AgentsRNA, MessengerMice, NudeAnimalsHumansMiceMice, Inbred BALB CCell Line, TumorLipidsDrug SynergismXenograft Model Antitumor Assays

Stichwörter der Autor:innen

Chemotherapy immunotherapy combinationIL12 mRNALipid nanoparticlesOxaliplatinProdrug

Substanzen

OxaliplatinProdrugsInterleukin-12Antineoplastic AgentsRNA, MessengerLipids

Autor:innen und Institutionen

  • School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs, Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministr…
  • Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia Medica, Yantai, 264000, China.
  • Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, 264117, China.
  • Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia Medica, Yantai, 264000, China. jpyin@yimm.ac.cn.
  • Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, 264117, China. caohaiqiang1@simm.ac.cn.
  • Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia Medica, Yantai, 264000, China. ylfu@simmyt.ac.cn.

ORCID-Profile: Yuanlei Fu

Förderung

  • National Natural Science Foundation of China
  • Department of Science and Technology of Shandong Province
  • Yantai Science and Technology Bureau

Zitieren

APA

Liu, H., Du, Y., Zhan, D., Yu, W., Li, Y., Wang, A., Yin, J., Cao, H., & Fu, Y. (2024). Oxaliplatin lipidated prodrug synergistically enhances the anti-colorectal cancer effect of IL12 mRNA. Drug Delivery and Translational Research. https://doi.org/10.1007/s13346-024-01540-x

Vancouver

Liu H, Du Y, Zhan D, Yu W, Li Y, Wang A, et al. Oxaliplatin lipidated prodrug synergistically enhances the anti-colorectal cancer effect of IL12 mRNA. Drug Delivery and Translational Research. 2024. doi:10.1007/s13346-024-01540-x

BibTeX
@article{Liu2024,
  author = {Liu, Hui and Du, Yating and Zhan, Desheng and Yu, Wenjun and Li, Yan and Wang, Aiping and Yin, Jianpeng and Cao, Haiqiang and Fu, Yuanlei},
  title = {Oxaliplatin lipidated prodrug synergistically enhances the anti-colorectal cancer effect of IL12 mRNA},
  journal = {Drug Delivery and Translational Research},
  year = {2024},
  doi = {10.1007/s13346-024-01540-x}
}
Kostenlos starten →